Joshua Armenia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua Armenia has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Josep Vicent Forment
AstraZeneca
23 shared publications - Mark J. O'Connor
Oncology Targeted Discovery, AstraZeneca, Cambridge, UK
22 shared publications - Natalia Lukashchuk
AstraZeneca (United Kingdom) 12 Cambridge
17 shared publications - Aleksandra Kmieciak
AstraZeneca (United Kingdom) 12 Cambridge
16 shared publications - Antoine Italiano
Gustave Roussy Cancer Institute, Paris-Saclay University, DITEP, Villejuif, France
16 shared publications - Armelle Vinceneux
Centre Léon Bérard 9 Lyon
16 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Geometric mean plasma concentrations of ceralasertib on Day 8 and Day 14 of Cycle 1 (blue) and Cycle 2 (orange) following receipt of ceralasertib 160 mg administered BID on days 1–14 of a 28-day cycle
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Geometric mean plasma concentrations of ceralasertib on Day 8 and Day 14 of Cycle 1 (blue) and Cycle 2 (orange) following receipt of ceralasertib 160 mg administered BID on days 1–14 of a 28-day cycle
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Ceralasertib 160 mg BID efficacy and time on treatment in genetic ATM subgroups determined by central testing
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Ceralasertib 160 mg BID efficacy and time on treatment in genetic ATM subgroups determined by central testing
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Representativeness of study participants
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Representativeness of study participants
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
CONSORT diagram for patients who started on ceralasertib 160 mg twice daily. aATM mutations and/or ATM protein loss by IHC: four patients total (two in cohort A and two in cohort B) were enrolled based on local tests reporting ATM variant of unknown significance alterations, but central confirmation did not identify ATM mutations (tumor/ctDNA NGS) or ATM protein deficiency (tumor IHC). bPer protocol, efficacy analyses were conducted in patients with ATM alterations (ATM mutations and/or ATM protein loss) identified by central testing. cDue to AE, consent withdrawal, death, patient decision, and other (n = 1 each). dUnknown (n = 3) or patient decision (n = 1).
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
CONSORT diagram for patients who started on ceralasertib 160 mg twice daily. aATM mutations and/or ATM protein loss by IHC: four patients total (two in cohort A and two in cohort B) were enrolled based on local tests reporting ATM variant of unknown significance alterations, but central confirmation did not identify ATM mutations (tumor/ctDNA NGS) or ATM protein deficiency (tumor IHC). bPer protocol, efficacy analyses were conducted in patients with ATM alterations (ATM mutations and/or ATM protein loss) identified by central testing. cDue to AE, consent withdrawal, death, patient decision, and other (n = 1 each). dUnknown (n = 3) or patient decision (n = 1).
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Safety summary for all patients who started on ceralasertib 160 mg BID
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Safety summary for all patients who started on ceralasertib 160 mg BID
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Individual characteristics of responders who started on ceralasertib 160 mg twice daily.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Individual characteristics of responders who started on ceralasertib 160 mg twice daily.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
CONSORT diagram for patients who started on ceralasertib 240 mg BID
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
CONSORT diagram for patients who started on ceralasertib 240 mg BID
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Most common AEs occurring at any grade in ≥15% of patients who started on ceralasertib 160 mg BID in each cohort by germline ATM mutation status
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Most common AEs occurring at any grade in ≥15% of patients who started on ceralasertib 160 mg BID in each cohort by germline ATM mutation status
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Progression-free survival for (a) patients who started on ceralasertib 160 mg BID in Cohort A, (b) patients with ATM protein expression ≤5% versus >5% versus unknown by IHC who started on ceralasertib 160 mg BID in Cohort A, (c) patients who started on ceralasertib 160 mg BID in Cohort B, and (d) patients with ATM protein expression ≤5% versus ATM >5% versus unknown by IHC who started on ceralasertib 160 mg BID in Cohort B
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Progression-free survival for (a) patients who started on ceralasertib 160 mg BID in Cohort A, (b) patients with ATM protein expression ≤5% versus >5% versus unknown by IHC who started on ceralasertib 160 mg BID in Cohort A, (c) patients who started on ceralasertib 160 mg BID in Cohort B, and (d) patients with ATM protein expression ≤5% versus ATM >5% versus unknown by IHC who started on ceralasertib 160 mg BID in Cohort B
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Adverse events observed in ≥2 patients who started on ceralasertib 240 mg BID in Cohort
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study
Adverse events observed in ≥2 patients who started on ceralasertib 240 mg BID in Cohort